Zogenix (ZGNX) Earns News Sentiment Score of 0.17
News articles about Zogenix (NASDAQ:ZGNX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.592964280808 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : December 6, 2017 (finance.yahoo.com)
- Zogenix, Inc. breached its 50 day moving average in a Bearish Manner : ZGNX-US : December 5, 2017 (finance.yahoo.com)
- Noteworthy Monday Option Activity: ZGNX, TTWO, HIIQ (stockoptionschannel.com)
- Zogenix (ZGNX) Announces New Positive Efficacy, Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome at AES (streetinsider.com)
- BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008 (ZGNX) (markets.businessinsider.com)
Zogenix (NASDAQ ZGNX) opened at $34.10 on Thursday. Zogenix has a one year low of $7.70 and a one year high of $42.60. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.71 and a current ratio of 2.71.
In related news, major shareholder Life Sciences Maste Perceptive acquired 300,000 shares of Zogenix stock in a transaction on Tuesday, October 3rd. The shares were bought at an average price of $37.50 per share, for a total transaction of $11,250,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 6.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/07/zogenix-zgnx-earns-news-sentiment-score-of-0-17.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Stock Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related stocks with our FREE daily email newsletter.